Immuneering (NASDAQ:IMRX) Upgraded at Chardan Capital

Chardan Capital upgraded shares of Immuneering (NASDAQ:IMRX) to a strong-buy rating in a report published on Monday,Zacks.com reports.

Several other research analysts have also weighed in on the company. Cantor Fitzgerald assumed coverage on Immuneering in a research report on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 target price on the stock. Wall Street Zen downgraded shares of Immuneering from a “hold” rating to a “sell” rating in a report on Monday, July 20th. Oppenheimer reaffirmed an “outperform” rating on shares of Immuneering in a report on Monday, June 1st. Needham & Company LLC lifted their target price on shares of Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research note on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Immuneering currently has an average rating of “Buy” and an average price target of $18.00.

Immuneering Price Performance

IMRX opened at $4.39 on Monday. The business has a 50 day moving average price of $4.60 and a two-hundred day moving average price of $4.98. The company has a market capitalization of $284.03 million, a price-to-earnings ratio of -3.75 and a beta of 0.43. Immuneering has a 1-year low of $2.90 and a 1-year high of $10.08.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.01). The company had revenue of $0.36 million during the quarter. Equities analysts expect that Immuneering will post -1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Immuneering

Several hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in shares of Immuneering by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after purchasing an additional 4,458 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Immuneering in the 4th quarter valued at $33,000. Southport Management L.L.C. boosted its position in shares of Immuneering by 1.8% in the 4th quarter. Southport Management L.L.C. now owns 277,501 shares of the company’s stock worth $1,826,000 after purchasing an additional 5,000 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Immuneering by 46.4% during the third quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company’s stock worth $137,000 after purchasing an additional 6,196 shares during the period. Finally, LPL Financial LLC increased its holdings in Immuneering by 30.0% in the fourth quarter. LPL Financial LLC now owns 29,125 shares of the company’s stock valued at $192,000 after purchasing an additional 6,725 shares during the last quarter. Institutional investors own 67.65% of the company’s stock.

Key Stories Impacting Immuneering

Here are the key news stories impacting Immuneering this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy” rating and a $14 price target, implying substantial upside from the reference price of $4.39. HC Wainwright starts Immuneering at Buy
• Positive Sentiment: Chardan Capital upgraded Immuneering to “Strong Buy,” adding to the favorable analyst sentiment around IMRX.
• Positive Sentiment: Immuneering reported a 17.3-month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib plus chemotherapy. The company said 84% of evaluable patients were weight-stable or gained weight after three months, supporting the drug’s potential efficacy and tolerability. Immuneering second-quarter financial results and business updates
• Positive Sentiment: The pivotal Phase 3 MAPKeeper 301 trial is enrolling and dosing patients across more than 30 locations. Management expects the company’s $182.7 million cash position to fund operations into 2029, reducing near-term financing pressure.
• Positive Sentiment: A peer-reviewed Cancer Research publication highlighted atebimetinib’s broad preclinical activity against RAS- and RAF-mutant tumors and potential for favorable tolerability.
• Neutral Sentiment: Upcoming catalysts include an expected Phase 2 atebimetinib and anti-PD-1 lung cancer study initiation in the second half of 2026, additional preclinical data in the fourth quarter, and MAPKeeper 301 topline results targeted for mid-2028.
• Negative Sentiment: Second-quarter adjusted results were slightly weaker than expected: Immuneering reported a $0.27 per-share loss versus the $0.26 consensus loss, while revenue was only $0.36 million.
• Negative Sentiment: The quarterly net loss widened to $17.3 million from $14.4 million a year earlier, with research and development costs rising to $14.0 million as clinical spending increased. IMRX remains unprofitable and has not yet completed a registrational trial.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.